Holly Gundacker

4.5k citations

41 papers · 3.2k indexed · 2 hit papers · h-index 18

Impact in

Virology top 0.5%
- HIV Research and Treatment
Hematology top 0.5%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation

Papers in

Hematology 17
- Acute Myeloid Leukemia Research 15
- Chronic Myeloid Leukemia Treatments 7
Microbiology 6
- Reproductive tract infections research 6

Co-authors: Frederick R. Appelbaum Marilyn L. Slovak Cheryl L. Willman Stephen H. Petersdorf John E. Godwin David R. Head Jeanne E. Anderson Michael D. Hughes
Journals: Blood (12 papers)Journal of Clinical Oncology (4 papers)British Journal of Haematology (3 papers)Clinical Infectious Diseases (2 papers)Journal of the International AIDS Society (2 papers)
Partner nations: United States Canada South Africa

In The Last Decade

Holly Gundacker

41 papers receiving 3.1k citations

Hit Papers

align trajectories log scale

Age and acute myeloid leukemia 2006 · 982 citations

Peers

Countries citing papers authored by Holly Gundacker

Since Specialization

Citations

This map shows the geographic impact of Holly Gundacker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Holly Gundacker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Holly Gundacker more than expected).

Fields of papers citing papers by Holly Gundacker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Holly Gundacker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Holly Gundacker. The network helps show where Holly Gundacker may publish in the future.

Co-authors

The 25 scholars most cited alongside Holly Gundacker, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Holly Gundacker Line = papers co-authored together Holly Gundacker links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother–infant pairs (MTN-043): a phase 3B, open-label, randomised trial The Lancet HIV ·Lisa Noguchi, Maxensia Owor, Nyaradzo Mgodi, Brenda Gati Mirembe, Sufia Dadabhai, Elizea Horne, Holly Gundacker, Barbra A. Richardson, Katherine Bunge, Rachel Scheckter, Mei Song, Mark A. Marzinke, Peter L. Anderson, Edward Livant, Cindy Jacobson, Jeanna Piper, Nahida Chakhtoura, Sharon L. Hillier, Jennifer E. Balkus	2025	3
2	Phase 1 randomized pharmacokinetic and safety study of a 90‐day tenofovir vaginal ring in the United States Journal of the International AIDS Society ·Albert Liu, Holly Gundacker, Barbra A. Richardson, Beatrice A. Chen, Craig Hoesley, Ariane van der Straten, Amanda Brown, May A. Beamer, Jennifer Robinson, Cindy Jacobson, Rachel Scheckter, Katherine Bunge, Jill L. Schwartz, Andrea R. Thurman, Jeanna Piper, Mark A. Marzinke, (unknown)	2024	1
3	Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal rings PLoS ONE ·Sharon L. Achilles, Clifton W. Kelly, Craig Hoesley, Diana Blithe, Joan Mut Vives, Barbra A. Richardson, Bríd Devlin, Craig W. Hendrix, Samuel M. Poloyac, Mark A. Marzinke, Holly Gundacker, Devika Singh, Jeanna Piper, Sherri Johnson, John Steytler, Beatrice A. Chen	2024	2
4	Acceptability of an extended duration vaginal ring for HIV prevention and interest in a multi-purpose ring PLoS ONE ·Marie C. D. Stoner, Erica N. Browne, Holly Gundacker, Aarati Tyagi, Beatrice A. Chen, Craig Hoesley, Rachel Scheckter, Jeanna Piper, Devika Singh, Mei Song, Albert Liu, Ariane van der Straten	2022	6
5	Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States Journal of the International AIDS Society ·Albert Liu, Ann-Marie Ginnever, Holly Gundacker, Blažej Neradilek, Craig Hoesley, Ariane van der Straten, Craig W. Hendrix, May A. Beamer, Cindy Jacobson, E. Cacciatori, Tanya M. Harrell, Katherine Bunge, Bríd Devlin, Jeremy Nuttall, Patrick Spence, John Steytler, Jeanna Piper, Mark A. Marzinke, (unknown)	2021	17
6	Risk Factors for Incidence of Sexually Transmitted Infections Among Women in a Human Immunodeficiency Virus Chemoprevention Trial: VOICE (MTN-003) Sexually Transmitted Diseases ·Zvavahera M. Chirenje, Holly Gundacker, Barbra A. Richardson, Lorna K. Rabe, Zakir Gaffoor, Gonasagrie Nair, Brenda Gati Mirembe, Jeanna Piper, Sharon L. Hillier, Jeanne Marrazzo	2017	11
7	Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432 Leukemia Research ·Harry P. Erba, Megan Othus, Roland B. Walter, Mark Kirschbaum, Martin S. Tallman, Richard A. Larson, Marilyn L. Slovak, Kenneth J. Kopecky, Holly Gundacker, Frederick R. Appelbaum	2013	15
8	Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial Annals of Oncology ·Michael A. Gordon, Holly Gundacker, Jacqueline Benedetti, J. S. Macdonald, Joaquina Baranda, Wendy J. Levin, Charles D. Blanke, Wafaa Elatre, Ouyan Peng, Jian Zhou, Heinz‐Josef Lenz, Michael F. Press	2013	68
9	Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17) Medical Oncology ·Peter H. Wiernik, Zhuoxin Sun, Holly Gundacker, Gordon W. Dewald, Marilyn L. Slovak, Elisabeth Paietta, Haesook T. Kim, Frederick R. Appelbaum, Peter A. Cassileth, Martin S. Tallman	2012	16
10	A phase II trial of azacitidine (NSC-102816) and gemtuzumab ozogamicin (NSC-720568) as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 acute myeloid leukemia: SWOG S0703 protocol—Report on the good-risk patients. Journal of Clinical Oncology ·Sucha Nand, Holly Gundacker, John E. Godwin, Cheryl L. Willman, Thomas H. Norwood, Harry P. Erba, Dianna S. Howard, Steven Coutré, Megan Othus, Frederick R. Appelbaum	2012	1
11	A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605 Blood ·Mikkael A. Sekeres, Holly Gundacker, Jeffrey E. Lancet, Anjali S. Advani, Stephen H. Petersdorf, Jane L. Liesveld, Deborah Mulford, Georgina Stobbs, Cheryl L. Willman, Frederick R. Appelbaum, Alan F. List	2011	66
12	Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia British Journal of Haematology ·Anjali S. Advani, Holly Gundacker, Olga Sala‐Torra, Jerald P. Radich, Raymond Lai, Marilyn L. Slovak, Jeffrey E. Lancet, Steven Coutré, Robert K. Stuart, Martha P. Mims, Patrick J. Stiff, Frederick R. Appelbaum	2010	49
13	Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia British Journal of Haematology ·Thomas R. Chauncey, Holly Gundacker, Mazyar Shadman, Alan F. List, Shaker R. Dakhil, Harry P. Erba, Marilyn L. Slovak, I‐Ming Chen, Cheryl L. Willman, Kenneth J. Kopecky, Frederick R. Appelbaum	2009	17
14	The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations British Journal of Haematology ·Frederick R. Appelbaum, Kenneth J. Kopecky, Martin S. Tallman, Marilyn L. Slovak, Holly Gundacker, Haesook T. Kim, Gordon W. Dewald, Hagop M. Kantarjian, Sherry R. Pierce, Elihu H. Estey	2006	187
15	Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706 Leukemia ·M. A. Hussein, Holly Gundacker, David R. Head, Laurence Elias, Kenneth A. Foon, David H. Boldt, Sheila M. Dobin, 熙大倉, G. Thomas Budd, Frederick R. Appelbaum	2005	2
16	Evaluation of Gemcitabine in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Southwest Oncology Group Phase II Study Investigational New Drugs ·Wolfram E. Samlowski, Holly Gundacker, J. Philip Kuebler, Jeffrey K. Giguere, Glenn Mills, David E. Schuller, John F. Ensley	2001	21
17	Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. PubMed ·Mitch Dowsett, C. Pfister, 杨翠婵, D.W. Miles, Stephen Houston, J. Arnold Verbeek, Holly Gundacker, A. Sioufi, I E Smith	1999	70
18	A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter New England Journal of Medicine ·Scott M. Hammer, David Katzenstein, Michael D. Hughes, Holly Gundacker, Robert T. Schooley, Richard Haubrich, W. Keith Henry, Michael M. Lederman, John Phair, Manette T. Niu, Martin Hirsch, Thomas C. Merigan Hit paper breakdown →	1996	768
19	The Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 Cells per Cubic Millimeter New England Journal of Medicine ·David Katzenstein, Scott M. Hammer, Michael D. Hughes, Holly Gundacker, J. Brooks Jackson, Susan A. Fiscus, Suraiya Rasheed, Tarek Elbeik, Richard C. Reichman, Anthony J. Japour, Thomas C. Merigan, Martin Hirsch	1996	393
20	Within-Subject Variation in CD4 Lymphocyte Count in Asymptomatic Human Immunodeficiency Virus Infection: Implications for Patient Monitoring The Journal of Infectious Diseases ·Michael D. Hughes, Daniel S. Stein, Holly Gundacker, Fred Valentine, John Phair, Paul A. Volberding	1994	94

About Holly Gundacker

Holly Gundacker is a scholar working on Hematology, Microbiology, Virology, Infectious Diseases and Genetics, having authored 41 papers that have together received 3.2k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (15 papers), HIV/AIDS Research and Interventions (13 papers), Acute Lymphoblastic Leukemia research (10 papers), Chronic Myeloid Leukemia Treatments (7 papers), Reproductive tract infections research (6 papers), HIV, Drug Use, Sexual Risk (5 papers), HIV Research and Treatment (4 papers) and Chronic Lymphocytic Leukemia Research (4 papers). The work is most often cited by research in Virology (804 citations), Hematology (1.4k citations), Infectious Diseases (946 citations), Genetics (378 citations) and Statistics and Probability (257 citations). Holly Gundacker has collaborated with scholars based in United States, Canada and South Africa. Frequent co-authors include Frederick R. Appelbaum, Marilyn L. Slovak, Cheryl L. Willman, Stephen H. Petersdorf, John E. Godwin, David R. Head, Jeanne E. Anderson, Michael D. Hughes, David Katzenstein and Scott M. Hammer. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, Clinical Infectious Diseases and Journal of the International AIDS Society.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact